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Abstract. 
 
Incubation of permeabilized cells with mi-
totic extracts results in extensive fragmentation of the 
pericentriolarly organized stacks of cisternae. The frag-
mented Golgi membranes are subsequently dispersed 
from the pericentriolar region. We have shown previ-
ously that this process requires the cytosolic protein mi-
togen-activated protein kinase kinase 1 (MEK1). Ex-
tracellular signal–regulated kinase (ERK) 1 and ERK2, 
the known downstream targets of MEK1, are not re-
quired for this fragmentation (Acharya et al., 1998). We 
now provide evidence that MEK1 is speciﬁcally phos-
phorylated during mitosis. The mitotically phosphory-
lated MEK1, upon partial proteolysis with trypsin, gen-
erates a different peptide population compared with 
interphase MEK1. MEK1 cleaved with the lethal factor 
of the anthrax toxin can still be activated by its up-
stream mitotic kinases, and this form is fully active in 
the Golgi fragmentation process. We believe that the 
mitotic phosphorylation induces a change in the con-
formation of MEK1 and that this form of MEK1 rec-
ognizes Golgi membranes as a target compartment.
Immunoelectron microscopy analysis reveals that treat-
ment of permeabilized normal rat kidney (NRK) cells 
with mitotic extracts, treated with or without lethal fac-
tor, converts stacks of pericentriolar Golgi membranes 
into smaller fragments composed predominantly of tu-
buloreticular elements. These fragments are similar in 
distribution, morphology, and size to the fragments ob-
served in the prometaphase/metaphase stage of the cell 
cycle in vivo.
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Introduction
 
The pericentriolarly organized Golgi apparatus of mam-
malian cells undergoes extensive fragmentation during
mitosis. This has been known for almost three decades
(Robbins and Gonatas, 1964; Lucocq et al., 1987). This
fragmentation is observed in mammalian cells and not in
plants, yeast, and flies during mitosis (Hirose and Ko-
mamine, 1989; Preuss et al., 1992; Stanley et al., 1997).
However, the extent of fragmentation, the fate of the frag-
mented Golgi membranes, the significance of this frag-
mentation, and above all, the mechanism of the Golgi
fragmentation are subject to debate.
 
To address these questions, we recently reconstituted
Golgi fragmentation in permeabilized cells. In this sys-
 
tem, normal rat kidney (NRK)
 
1
 
 cells are permeabilized,
washed to remove cytosolic proteins, and then incubated
with mitotic extracts prepared from NRK cells arrested in
 
mitosis. The reaction mixture is incubated at 32
 
8
 
C for 60
min, and the organization of the Golgi membranes moni-
tored by fluorescence microscopy using Golgi-specific an-
tibodies. We have shown that mitotic cytosol is highly en-
riched in cdc2 kinase activity, but that the cdc2 kinase
activity is not required for Golgi fragmentation and dis-
persal of the Golgi fragments from the pericentriolar re-
gion. On the other hand, inactivation of the mitogen-acti-
vated protein kinase kinase 1 (MEK1) by drugs, or
depletion of MEK1 by affinity chromatography or frac-
tionation of mitotic cytosol, results in a loss of Golgi frag-
mentation. Surprisingly, the cytosolic downstream targets
 
of MEK1, i.e., extracellular signal–regulated kinase (ERK) 1
 
and ERK2 (MAPKs), are not required for the MEK1-
dependent Golgi fragmentation (Acharya et al., 1998).
We now provide evidence that MEK1 undergoes spe-
cific activation by phosphorylation during mitosis. The
mitosis-specific activation of MEK1 is required for the
conversion of the Golgi into tubuloreticular elements,
and this fragmentation step does not require cdc2 ki-
nase.
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Materials and Methods
 
Reagents, Antibodies, and Cells
 
All biochemical reagents were obtained from the sources described before
unless otherwise mentioned (Acharya et al., 1998). Nickel agarose beads
were purchased from Amersham Pharmacia Biotech. Rabbit anti–rat
mannosidase II (MannII) and the anti–NH
 
2
 
-terminal MEK1 antibody
were kindly provided by Drs. Kelly Moremen (University of Georgia,
Athens, GA) and James Ferrell (Stanford University, Stanford, CA), re-
spectively. The anti–COOH-terminal MEK1 was purchased from Santa
Cruz Biotechnology. The phospho-MEK antibody was purchased from
New England Biolabs, Inc. Drs. Cesare Montecucco (University of Padua,
Padua, Italy) and Nick Duesbery (Van Andel Research Institute, Grand
Rapids, MI) kindly provided lethal factor. Recombinant His-MEK1 was a
kind gift from Drs. Jocelyn Wright (SUGEN, South San Francisco, CA)
and Natalie Ahn (University of Colorado at Boulder, Boulder, CO). Re-
combinant 
 
D
 
N7-MEK1 was a gift from Dr. Nick Duesbery. All EM re-
agents were purchased from the sources described before (Takizawa et al.,
1993). Trypsin was purchased from Calbiochem.
All tissue culture cells are grown in complete medium consisting of
 
a
 
-MEM (Gibco) with 10% FCS, 100 U/ml penicillin, and 100 
 
m
 
g/ml strep-
tomycin at 37
 
8
 
C in a 5% CO
 
2
 
 incubator.
 
Preparation of Mitotic and Interphase Extracts
 
Cytosol from NRK cells arrested in mitosis or interphase was prepared as
described before (Acharya et al., 1998). Cell permeabilization and assay
for Golgi fragmentation by mitotic extracts were carried out as described
before (Acharya et al., 1998).
 
Incubation of Permeabilized Cells with Lethal
Factor–treated Cytosol
 
Mitotic extract was pretreated with lethal factor (30 ng/ml) for 10 min at
32
 
8
 
C. This mixture and an ATP regeneration system were then added to
semi-intact cells and the incubation carried out for 1 h at 32
 
8
 
C. When PD
and olomoucine were used, these compounds were added to cytosol pre-
treated with lethal factor at a final concentration of 75 and 200 
 
m
 
M, re-
spectively. The mixture was incubated for 10 min at 32
 
8
 
C in the presence
of an ATP regeneration system and then added to semi-intact cells for 60
min at 30
 
8
 
C to monitor effects on Golgi fragmentation using the perme-
abilized cell system.
 
Incubation of Recombinant MEK with Interphase and 
Mitotic Extract
 
In a typical preparation, 20 
 
m
 
g of recombinant His-MEK1 (wild-type or
 
D
 
N7) was incubated in a total volume of 80 
 
m
 
l with interphase or mitotic
extract at a final concentration of 4 mg/ml. The kinase buffer used was
composed of 50 mM Hepes, pH 7.2, 10 mM MgCl
 
2
 
, 1 mM DTT, 500 
 
m
 
M
ATP, and 30 
 
m
 
Ci [
 
32
 
P]ATP. The reaction mixture was incubated for 30
min at 30
 
8
 
C. At the end of the incubation, His-MEK1 was adsorbed of
nickel beads, resuspended in 50 mM Hepes, pH 7.2, 200 mM NaCl, 10 mM
 
b
 
-mercaptoethanol, 10 mM imidazole, 10% glycerol, and finally eluted
with 200 mM imidazole.
 
Tryptic Digestion of MEK1
 
His-MEK1 incubated with mitotic or interphase extract as described
above was incubated at room temperature with trypsin (1:100, enzyme/
substrate in wt/wt). At the indicated times, aliquots were removed and the
reaction terminated by boiling the samples in Laemmli sample buffer. The
samples were analyzed by SDS-PAGE followed by autoradiography and
immunoblotting with the indicated antibodies as described in the figure
legends.
 
Assay of Enzymatic Activity of MEK1
 
The procedure was the same as described before (Acharya et al., 1998).
 
Immunoelectron Microscopy
 
NRK cells were grown in special petri dishes (Matteck Corporation; Tak-
izawa et al., 1993), permeabilized as described above, and processed for
immunoelectron microscopy as described by Polishchuk et al. (1999). For
the analysis of intact mitotic cells, NRK cells were incubated for 12 h with
2.5 
 
m
 
g/ml aphidicolin to arrest cells in S phase. The cells were washed by
repeated changes of medium and placed in fresh medium. After 6–8 h, the
mitotic cells were collected by gentle shake-off and processed for immu-
noelectron microscopy using anti-ManII antibody followed by HRP-con-
jugated secondary antibody. Ultrathin sections (80 nm) were observed at
80 KeV with either a JEOL 100C
 
3
 
 or 2000F
 
3
 
 electron microscope, and
semithin sections (0.5 
 
m
 
M) at 400 KeV with a JEOL 4000E
 
3
 
 intermediate
voltage electron microscope. The mitotic stages were assigned as de-
scribed by Lucocq et al. (1987).
 
Results
 
MEK1 Is Hyperphosphorylated by Mitotic Extracts
 
It is known that activation of MEK1 is necessary for a
number of mitosis-specific events in somatic cells (Ach-
arya et al., 1998; Shapiro et al., 1998; Zecevic et al., 1998).
To test whether the mitotic form of MEK1 is in any way
different from its activated counterpart found in the non-
mitotic stages, wild-type His-tagged MEK1 was expressed
in 
 
Escherichia coli
 
 and the recombinant purified protein
incubated with mitotic extracts or interphase extracts in
the presence of [
 
32
 
P]ATP at 30
 
8
 
C. MEK1 was isolated
from the reaction mixtures by adsorption on Ni beads and
analyzed by SDS-PAGE and autoradiography (Fig. 1 A).
Quantitation of the autoradiogram revealed a fourfold in-
crease in phosphorylation of MEK1 incubated with mi-
totic vs. interphase extract (Fig. 1 C).
Figure 1. MEK1 is hyperphosphorylated during mitosis and less
reactive with the phospho-MEK antibody. His-MEK1 was incu-
bated with mitotic and interphase extracts and [32P]ATP for 30
min at 308C. The tagged protein was isolated on Ni beads and an-
alyzed by SDS-PAGE followed by autoradiography (A) and sub-
jected to Western blotting with the phospho-MEK1 antibody
(B). The quantitation of the autoradiogram and the Western blot
is shown in C and D, respectively. His-tagged MEK1 incubated
with mitotic extract is fourfold more phosphorylated and twofold
less reactive with the phospho-MEK1 antibody compared with
incubation in interphase extracts. a.u., arbitrary units. 
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An antibody that recognizes a generically activated
form of MEK1 (phospho-MEK1 antibody) was used to
test whether this antibody recognizes the mitotically phos-
phorylated form of MEK1 compared with MEK incubated
with interphase cytosol. The phospho-MEK1 antibody
recognizes an activated form of MEK1 phosphorylated at
Ser217 and Ser221. This form of MEK1 activation occurs
upon the incubation of cells with growth factors or cyto-
kines, or during membrane depolymerization and calcium
influx (Crews et al., 1992; Alessi et al., 1994; Robinson and
Cobb, 1997). The Ser217- and Ser221-phosphorylated
MEK1 activates the downstream kinases called ERKs. An
important question is whether the mitotically phosphory-
lated MEK1 is in some way different from the generically
activated form of MEK1. To test this, His-MEK1 was in-
cubated with mitotic cytosol or interphase cytosol and
ATP. MEK1 was isolated on Ni beads, released from the
beads by imidazole treatment, and analyzed by Western
blotting with the phospho-MEK1 antibody. The phospho-
MEK1 antibody is twofold less reactive with mitotically
activated MEK1 compared with interphase MEK1 (Fig. 1,
B and D). Thus, even though MEK1 is hyperphosphory-
lated during mitosis, it is less reactive with the antibody
that recognizes the generically phosphorylated (nonmi-
totic) form of MEK1.
 
Mitotically Activated MEK1 Is Differentially 
Proteolyzed by Trypsin with Respect to Its
Interphase Counterpart
 
His-tagged MEK1 was incubated with either interphase or
the mitotic extract in the presence of [
 
32
 
P]ATP for 30 min
at 30
 
8
 
C. The tagged protein was isolated on Ni beads and
subjected to limited tryptic digestion. At various times the
reaction was analyzed by SDS-PAGE and autoradiogra-
phy and Western blotting with either anti–COOH-termi-
nal or NH
 
2
 
-terminal–specific MEK1 antibody or the phos-
pho-MEK1 antibody. Interestingly, trypsin digestion of
mitotically activated MEK, and not interphase MEK1, re-
sults in the production of a prominent phosphorylated
polypeptide of 
 
z
 
20 kD (Fig. 2 A). This polypeptide is rec-
ognized by the COOH-terminal–specific antibody, but not
by the phospho-MEK1–specific antibody or the NH
 
2
 
-ter-
minal MEK1 antibody (Fig. 2 B). The mitotic form of
MEK1 is less susceptible to digestion with trypsin com-
pared with its interphase counterpart (Fig. 2 B). Thus, the
overall susceptibility and pattern of trypsin digestion is dif-
ferent in MEK1 incubated with interphase vs. the mitotic
cytosol. The 20-kD polypeptide of MEK1 is not generated
when it is incubated with interphase extracts. This would
explain the increase in phosphorylation of MEK1 during
mitosis, without any increase in reactivity to the phospho-
MEK1 antibody. We propose that MEK1, upon phosphor-
ylation by the mitotic extracts, undergoes a change in con-
formation and this new conformation is differentially
sensitive to proteolysis, rendering it active for the Golgi
fragmentation process.
 
Lethal Factor Cleaves MEK1 without Affecting Its 
Activation by the Upstream Kinase
 
Bacterial anthrax toxin contains a protein called lethal fac-
tor, which cleaves the first eight amino acids from the NH
 
2
 
terminus of MEK1 (Duesbery et al., 1998; Vitale et al.,
1998). This cleaved form of MEK1 is incapable of binding
its downstream target, the MAPKs ERK1 and ERK2. We
asked whether the mitotic-specific phosphorylation is pos-
sible without the first eight amino acids of MEK1, and
whether cleavage with the lethal factor affects MEK1 ac-
tivity in the Golgi fragmentation process. To address the
first question, we used a recombinant form of MEK1 lack-
ing the first seven amino acids. The purified recombinant
His-tagged 
 
D
 
N7-MEK1 was incubated with the mitotic or
the interphase cytosol and [
 
32
 
P]ATP for 30 min at 32
 
8
 
C.
The 
 
D
 
N7-MEK1 was isolated on Ni beads and then ana-
lyzed by SDS-PAGE followed by autoradiography and
Western blotting with the anti–phospho-MEK antibody.
Incubation of 
 
D
 
N7-MEK1 with mitotic extracts results in a
fourfold increase in 
 
32
 
P incorporation, and the mutant pro-
tein is about fourfold less reactive with the phospho-
Figure 2. Partial proteolysis of mitotic MEK1 with trypsin gener-
ates a specific 20-kD phosphopeptide. His-tagged MEK1 was in-
cubated with mitotic or interphase extract and [32P]ATP for 30
min at 308C. MEK1 was isolated on Ni beads and released by
treatment with imidazole. The phosphorylated His-MEK1 was
incubated with trypsin, and at the times shown, analyzed by SDS-
PAGE followed by autoradiography (A) and Western blotting
with the phospho-MEK1 antibody and antibody against the
COOH- and the NH2-terminal of MEK1 (B). Treatment with
trypsin results in the generation of a 20-kD phosphorylated spe-
cies in mitotically activated MEK1 (shown by arrow in A). The
20-kD phosphorylated peptide of MEK1 does not react with the
phospho-MEK1 antibody, and reacts with the COOH- and not
the NH2-terminal–specific anti-MEK1 antibody. Ab CT, anti-
MEK COOH-terminal antibody; Ab NT, anti-MEK NH2-termi-
nal antibody; Ab pMEK, phospho-MEK antibody. M and I are
the mitotic and interphase extracts, respectively. 
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MEK1 antibody compared with its counterpart incubated
with the interphase cytosol (Fig. 3). Therefore, the wild-
type MEK1 and the 
 
D
 
N7-MEK1 have the same properties
with respect to phosphorylation and reaction with the
phospho-MEK1 antibody upon incubation with mitotic
extract.
Does the treatment of mitotic cytosol with lethal factor
affect its Golgi fragmentation activity? To test this, mitotic
cytosol was incubated with purified recombinant lethal
factor at 32
 
8
 
C for 10 min and the reaction was then divided
into three aliquots and used for the following analyses:
(a) The reaction mixture was analyzed by SDS-PAGE
followed by Western blotting with the COOH-terminal–
specific MEK1 antibody and the NH
 
2
 
-terminal–specific
antibody (Fig. 4). Treatment of the cytosol with lethal fac-
tor cleaves MEK1. Western blotting with the COOH-ter-
minal–specific antibody reveals a shift in the molecular
weight of MEK1 (Fig. 4, top panel). As expected, the NH
 
2
 
-
terminal–specific antibody fails to react with MEK1 in cy-
tosol treated with lethal factor (Fig. 4, lower panel), indi-
cating that this treatment is effective in cleaving MEK1.
(b) MEK1 was immunoprecipitated from the lethal fac-
tor–treated or -untreated cytosol using the COOH-termi-
nal–specific anti-MEK1 antibody. The immunoprecipi-
tated proteins were incubated with purified recombinant
ERK2 for 30 min in the presence of ATP at 30
 
8
 
C. The re-
action was then centrifuged to remove MEK1, and the su-
pernatant containing ERK2 was incubated with myelin ba-
sic protein (MBP), [
 
32
 
P]ATP at 30
 
8
 
C for 30 min. The
reaction was then analyzed by SDS-PAGE and autora-
diography and the phosphorylation of MBP taken as a
measure of ERK activation. Fig. 5 A shows that cleavage
with lethal factor inactivates the ability of MEK1 to acti-
vate ERK.
(c) Lethal factor–treated mitotic cytosol was incubated
with permeabilized NRK cells that had been prewashed
with 1 M KCl. After 60 min of incubation at 32
 
8
 
C, the cells
were fixed for immunofluorescence using anti-ManII anti- Figure 3. DN7-MEK1 is hyperphosphorylated with mitotic ex-
tracts. His-tagged DN7-MEK1 was incubated with the mitotic
and interphase extracts and [32P]ATP for 30 min at 308C. The
tagged version of MEK1 was isolated on Ni beads, released from
the beads with imidazole, and analyzed by SDS-PAGE and auto-
radiography (A) and Western blotting with the phospho-MEK1
antibody (B). The quantitation of the results show that His-DN7-
MEK is fourfold more phosphorylated when incubated with the
mitotic extracts (C) and fourfold less reactive with the phospho-
MEK1 antibody (D). a.u., arbitrary units.
Figure 4. Lethal factor
cleaves the first eight amino
acids from the NH2 terminus
of MEK1. Mitotic extracts
were incubated with lethal
factor for 10 min at 328C. The
samples were then analyzed
by SDS-PAGE and Western blotted with the antibody against
the COOH terminus or the NH2 terminus of MEK1. The lethal
factor–cleaved MEK1 is increased in mobility and not reactive
with the NH2-terminal–specific antibody. 2, untreated mitotic
extracts; LF, lethal factor–treated mitotic extracts; C, anti–C-ter-
minal MEK antibody; N, NH2-terminal MEK antibody.
Figure 5. Lethal factor–cleaved MEK1 does not activate ERKs
but causes Golgi fragmentation. Mitotic extracts were incubated
with lethal factor for 10 min at 328C. MEK1 was immunoprecipi-
tated with the C-terminal–specific antibody and the complex
collected on protein G–Sepharose. The MEK1 on protein
G–Sepharose was incubated with ERK2 and ATP for 30 min at
308C. The sample was centrifuged and the supernatant containing
ERK incubated with MBP and [32P]ATP for 30 min at 308C. The
reaction was then analyzed by SDS-PAGE and autoradiography
and the level of MBP phosphorylation (a measure of ERK acti-
vation) quantitated by PhosphorImager. The results show that le-
thal factor treatment inactivates the activity of MEK1 towards its
substrate ERK2 (A). The aliquot of the cytosol that had been
treated with lethal factor (see above) was incubated with perme-
abilized cells and an ATP regeneration system at 328C for 60 min.
For comparison, an aliquot of cytosol treated with the buffer
used for dissolving lethal factor only (2) was similarly tested for
effects on the Golgi fragmentation in the permeabilized cell sys-
tem. The cells were analyzed for the effects on Golgi morphology
using anti-ManII antibody by fluorescence microscopy. The re-
sults were quantitated by counting 200 cells on two different cov-
erslips and show that lethal factor cleavage does not affect the
Golgi fragmentation activity of MEK1 (B). 
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body. 200 cells on two different coverslips were counted,
and this quantitation revealed that lethal factor has no ef-
fect on the ability of mitotic extracts to fragment Golgi
membranes (Fig. 5 B).
 
Is cdc2 Kinase Involved in the Fragmentation of Golgi 
Membranes with Mitotic Extracts Treated with
Lethal Factor?
 
We have shown previously that cdc2 kinase is not required
for conversion of the pericentriolar Golgi membranes into
smaller fragments (punctate structures at the light micros-
copy level; Acharya et al., 1998). To confirm that this is
also the case with lethal factor–treated mitotic extracts,
they were incubated in the presence of the generic inhibi-
tor of cdc2 kinase activity, olomoucine. This mixture was
then applied to permeabilized cells (washed with 1 M KCl)
and an ATP regenerating system at 32
 
8
 
C for 60 min. The
samples were visualized by fluorescence microscopy. Re-
sults show that under conditions where cdc2 kinase is inac-
tive (the cdc2 kinase activity measured in the histone H1
phosphorylation was completely inhibited under these
conditions [data not shown]), lethal factor–treated mitotic
cytosol can convert the pericentriolarly organized stacks
of Golgi cisternae into smaller structures (Fig. 6, A and B).
We have shown previously that an inhibitor of MEK1
activation called PD 98059 (Alessi et al., 1995; Dudley et
al., 1995) inhibits Golgi fragmentation (Acharya et al.,
1998). Does this compound affect the Golgi fragmentation
activity of lethal factor–treated mitotic cytosol? To test
this, mitotic cytosol was incubated with lethal factor for 10
min at 32
 
8
 
C and then incubated with PD. The reaction was
then supplied to permeabilized NRK cells, prewashed with
1 M KCl and an ATP regenerating system for 60 min at
32
 
8
 
C. The analysis of the cells at the light microscopy level
using the anti-ManII antibody reveals a complete inhibi-
tion of the Golgi fragmentation (Fig. 6, A and B). Thus, a
PD-sensitive activation of MEK1 is necessary for Golgi
fragmentation. These results confirm and further support
our proposal that the fragmentation of the pericentriolar
Golgi stacks during mitosis is by a PD-sensitive, lethal fac-
tor–insensitive, activation of MEK1, and does not require
active cdc2 kinase.
 
The Organization of Golgi Membranes in Permeabilized 
Cells Treated with the Mitotic Extracts
 
We have shown before that mitotic cytosol causes exten-
sive fragmentation of the pericentriolar Golgi membranes
(Acharya et al., 1998). However, the analysis was per-
formed only at the light microscopy level and the organi-
zation or the morphology of the fragmented Golgi mem-
branes was not reported because of technical limitations,
which we have now resolved. NRK cells were permeabi-
lized, washed with 1 M KCl, and then incubated with mi-
totic cytosol and an ATP regenerating system. A light
microscopic analysis reveals the conversion of the peri-
centriolar Golgi apparatus (Fig. 7 A) into small punctate
structures distributed throughout the cells. A similar prep-
aration was processed for immunoelectron microscopy
with an antibody to the cis/medial specific Golgi protein
ManII. Thin sections of the cells revealed the presence of
ManII in small structures composed of small cisternae and
tubuloreticular elements (Fig. 7, B and C–E). Fig. 7 F
shows the control Golgi membranes by immunofluores-
cence and immunoelectron microscopy with anti-ManII
antibody in intact nonmitotic NRK cells. A calculation of
the size of the Golgi fragments stained with ManII anti-
body reveals that the stacks of Golgi cisternae of 1.5 
 
m
 
m
average size are converted into tubuloreticular fragments
of 
 
z
 
0.60 
 
m
 
m in size by the action of mitotic cytosol. Incu-
bation of the permeabilized cells with cytosol made from
interphase cells and an ATP regeneration system at 32
 
8
 
C
for 60 min does not affect the pericentriolar organization
of the Golgi membranes (data not shown).
Figure 6. PD and not the cdc2 kinase inhibitor olomoucine in-
hibit fragmentation of Golgi membranes with mitotic extracts
treated with lethal factor in permeabilized cells. Mitotic extracts
treated with the lethal factor as described in the legend to Fig. 5
were incubated with either PD or olomoucine and then applied
to permeabilized cells. The organization of the Golgi membranes
was analyzed by fluorescence microscopy using the anti-ManII
antibody (A) and quantitated (B) as described in the legend to
Fig. 5. PD and not olomoucine treatment inhibits the fragmenta-
tion of mitotic extracts pretreated with lethal factor. 
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Figure 7. Mitotic extracts convert stacks of pericentriolar Golgi membranes into
small tubules and reticular elements in permeabilized cells. NRK cells permeabi-
lized and washed with 1 M KCl were incubated with mitotic extracts and an ATP
regenerating system at 328C for 60 min. The cells were then fixed and analyzed for
immunoelectron microscopy using anti-ManII antibody. Thin sections of the cells
were visualized and a representative section is shown (B). Treatment with mitotic
extracts causes fragmentation and dispersal of Golgi membranes stained with
ManII antibody (A, fluorescence microscopic analysis) and the fragments are in
the form of small tubules and reticular elements (C–E). (F) a and b are the immuno-
fluorescence and immunoelectron microscopic images of intact interphase cells
stained with the Golgi-specific anti-ManII antibody. Bars: 500 nm (B); 200 nm
(C–E); and 1 mm (F). 
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The Relationship between the Golgi Fragments 
Generated by Mitotic Cytosol In Vitro and the In Vivo 
Mitotic Golgi Fragments
 
Mitotic extracts treated with the lethal factor were incu-
bated with permeabilized NRK cells and an ATP regener-
ating system at 32
 
8
 
C for 60 min. The samples were fixed
and thin sections analyzed by immunoelectron microscopy
using anti-ManII antibody. The results of the analysis are
shown in Fig. 8 C. Golgi stacks are converted into tubu-
loreticular membranes and small cisternae in cells incu-
bated with mitotic extract treated with lethal factor. For
comparison, we have included the intact mitotic cells
(prometaphase/metaphase; Fig. 8 A) and permeabilized
cells treated with mitotic extracts (without the lethal factor
treatment; Fig. 8 B). The results show that in all cases the
Golgi membranes stained with ManII antibody are com-
posed of tubuloreticular membranes. The size of these tu-
buloreticular elements on average is 
 
z
 
0.60 
 
m
 
m. The Golgi
fragments in mitotic cells, permeabilized cells incubated
with mitotic extracts that are treated with or without the
lethal factor, appear morphologically similar and are of
similar size and distribution.
 
Discussion
 
We have shown that MEK1 is activated specifically during
mitosis, and that this activation does not require the pres-
ence of the first eight amino acids of MEK. A comparison
of the ManII-stained structures in intact mitotic cells in
vivo and in our permeabilized cell system shows Golgi
membranes in the form of small tubules and reticular
membranes. These structures are highly similar in mor-
Figure 8. Golgi fragments generated with
mitotic extracts treated with or without the
lethal factors are the same as those observed
in the prometaphase/metaphase mitotic cells
in vivo. Intact mitotic cells in the pro-
metaphase/metaphase stage of the cell cycle
(A), permeabilized cells incubated with mi-
totic extracts treated with the lethal factor
(C) or untreated (B) were analyzed by im-
munoelectron microscopy using anti-ManII
antibody. Thin sections of the samples were
visualized and a representative section of
ManII staining Golgi structures is shown.
The Golgi fragments are composed of short
tubules, reticular elements, and vesicles in
all three preparations. Bars, 200 nm. 
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phology, size (0.60 
 
m
 
m), and distribution (small elements
dispersed in the cell), strengthening the proposal that our
assay reconstitutes the first step in Golgi fragmentation
during mitosis. This process was MEK1-dependent and
cdc2 kinase–independent.
 
Mitosis-specific Activation of MEK1
 
Our results show that MEK1 is hyperphosphorylated in
mitosis. Interestingly, this hyperphosphorylation results in
a decreased affinity towards the generic phospho-MEK1
antibody. The mitosis-specific activation of MEK1 is in-
hibited by pretreatment with PD but not with the lethal
factor of anthrax toxin. Thus, the fragmentation of the
pericentriolar Golgi stacks into tubuloreticular elements is
due to a PD-sensitive and lethal factor–insensitive activity
of MEK1, which occurs during mitosis. We believe that
this mitosis-specific activation by phosphorylation is re-
sponsible for a change in the substrate specificity of
MEK1. The 20-kD phosphopeptide of MEK1 is generated
only as a result of mitosis-specific phosphorylation. It is
also interesting to note that Golgi fragmentation by
MEK1 does not require the only known substrates, ERK1
and ERK2. Thus, specific activation by phosphorylation
changes the substrate specificity of MEK1 so that it can
cause Golgi fragmentation without using the ERKs. How
a change in the substrate specificity is achieved based on
the phosphorylation state of MEK1 is currently not
known.
Warren and colleagues have argued that MEK1 is not
required for entry into mitosis and Golgi fragmentation
(Lowe et al., 1998). This interpretation is based on experi-
ments in which they loaded cells with the lethal factor and
found that this resulted in inactivation of ERK1 and
ERK2. The cells entered mitosis and the Golgi mem-
branes were found as clusters of small vesicles (Lowe et
al., 1998). However, we can explain their findings based on
our results that cleavage with lethal factor prevents activa-
tion of ERK1 and ERK2, but this form of MEK is still acti-
vated by its upstream kinase and can convert Golgi mem-
branes into tubuloreticular elements (Figs. 5, 7, and 8).
It has also been argued that MEK activity is lower in mi-
tosis and that this is consistent with the inhibition of
MEK1 activity by cdc2 kinase. Lowe et al. (1998) sug-
gested that the low MEK1 activity is consistent with
MEK1 not being a key mitotic regulator of Golgi fragmen-
tation. We argue that MEK1 activity is low as measured by
the activation of ERK1 and ERK2 phosphorylation. How-
ever, its activity towards other potential substrates, such as
those involved in Golgi fragmentation, spindle dynamics,
and checkpoint control may be regulated by an alternative
mechanism (Wang et al., 1997; Acharya et al., 1998; Sha-
piro et al., 1998; Zecevic et al., 1998).
The fact that cdc2 kinase inhibits MEK1 activation is
based on in vitro analysis. Whether this also happens in
vivo is not known (Rossomondo et al., 1994). Although
cdc2 kinase is required for entry into mitosis and controls
the fate of many cellular process, this does not mean that
all the mitotic-specific events are regulated by cdc2 kinase
or that all phosphorylations by cdc2 kinase (in vitro and
in vivo) have a physiological significance (Moreno and
Nurse, 1990). For example, in the case of lamin disassem-
 
bly, a recent report shows that this involves sequential
phosphorylation first by PKC, which is then followed by
cdc2 kinase (Collas, 1999).
Warren and colleagues reported that 50 
 
m
 
M completely
inactivated MEK1 in vivo in cells grown in the presence of
serum without affecting the ability of cells to enter mitosis
or undergo Golgi fragmentation (Lowe et al., 1998). We
found that 80 
 
m
 
M PD is required for MEK1 inactivation
and inhibits the entry of NRK cells into mitosis (data not
shown). We carried out this experiment as follows: NRK
cells were treated with aphidicolin (2.5 
 
mg/ml) in complete
medium (containing 10% FBS) for 12 h at 378C. Cells were
washed extensively to remove aphidicolin and incubated
with fresh medium containing serum. The cells were then
washed and incubated with complete medium containing
either PD (80 mM) or DMSO (the solvent for PD) at 378C.
After 5 h, the cells were analyzed by fluorescence micros-
copy with the DNA-specific fluorescent dye HOECHST
33258 to quantitate the mitotic index. In DMSO-treated
cells, 30% of the cells were in mitosis, whereas only 5% of
the cells were in mitosis in incubations with PD. Our ob-
servations are supported by those of Wright et al. (1999),
who have recently shown that when PD is applied to cells
grown in defined conditions (and not in complete medium
containing serum), MEK1 is inhibited and the cells are ar-
rested in G2 (Wright et al., 1999).
What Is the Ultimate Fate of Golgi Membranes
during Mitosis?
Our data show that MEK1 is involved in the breakdown of
the pericentriolarly organized Golgi membranes into nu-
merous smaller tubuloreticular elements (Acharya et al.,
1998; this work). Similar fragments have also been found
in cells undergoing mitosis naturally and in cells induced
to enter mitosis by okadaic acid treatment (Lucocq, 1992;
Lucocq et al., 1995). But do these fragments undergo fur-
ther processing into clusters of vesicles or fuse with the
ER (Thyberg and Moskalewski, 1992; Zaal et al., 1999)?
If the Golgi membranes are converted into numerous
smaller fragments (resembling tubuloreticular elements),
this should be sufficient for their partitioning into the
daughter cells. But there is a large volume of data showing
that Golgi membranes are converted into clusters of vesi-
cles in mitotic cells (Lucocq et al., 1987; Warren 1993).
Jesch and Linstedt (1998) also find that Golgi membranes
are converted into vesicles of 60 nm diameter and can be
separated from the ER in HeLa cells treated with nocada-
zole for 24 h. It is possible, however, that these cells are
apoptotic not mitotic, and Sesso et al. (1999) have shown
that in apoptotic cells, Golgi membranes are found distrib-
uted throughout the cell in the form of clusters of 40–60-
nm vesicles. Is Golgi vesiculation a property of cells under-
going mitosis, apoptosis, or both?
In summary there is a general agreement in the field
that the pericentriolarly organized Golgi apparatus is con-
verted into smaller elements (tubuloreticular elements
and smaller stacks) during mitosis. It remains to be deter-
mined whether these fragments undergo further process-
ing to form vesicles or fuse with the ER. A comprehensive
understanding of Golgi partitioning will require a resolu-
tion of this issue, as the process by which Golgi mem-Colanzi et al. MEK-dependent Mitotic Golgi Fragmentation 339
branes are rebuilt into stacks (postmitosis) will differ de-
pending on the final domicile of the Golgi during mitosis.
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